December 18, 2019
Update on progress for drug development programs VP01 (C21) and VP02 (IMiD)
Media
December 18, 2019
Nordic Nanovector awarded NOK 12 million in funding from the Norwegian Research Council to advance Alpha37, a targeted alpha therapy for B-cell cancers
December 17, 2019
Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ)
December 12, 2019
SVCA:s pris för Årets affär går till HealthCap VI LP för sin avyttring av Wilson Therapeutics AB
December 12, 2019
Nordic Nanovector provides update on LYMRIT 37-05 Phase 1 DLBCL trial
December 11, 2019
GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history
December 09, 2019
The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France
December 09, 2019
BONESUPPORTTM CERTiFy STUDY ON CERAMENT® BONE VOID FILLER NOW PUBLISHED IN THE JOURNAL OF BONE AND JOINT SURGERY
December 09, 2019
Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual
December 08, 2019
Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019